NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $2,417,149 | +86.9% | 2,912,228 | +57.6% | 0.09% | +66.1% |
| Q1 2023 | $1,293,320 | +37.3% | 1,847,600 | -0.2% | 0.06% | +43.6% |
| Q4 2022 | $941,938 | -57.2% | 1,850,566 | -46.2% | 0.04% | -54.1% |
| Q3 2022 | $2,200,000 | -37.9% | 3,436,935 | 0.0% | 0.08% | -37.0% |
| Q2 2022 | $3,540,000 | -45.7% | 3,436,935 | -0.8% | 0.14% | -33.5% |
| Q1 2022 | $6,515,000 | -61.3% | 3,465,435 | -0.7% | 0.20% | -47.0% |
| Q4 2021 | $16,826,000 | -33.6% | 3,490,835 | -0.5% | 0.38% | -13.3% |
| Q3 2021 | $25,357,000 | -29.9% | 3,507,235 | -10.5% | 0.44% | -17.4% |
| Q2 2021 | $36,175,000 | -28.6% | 3,919,235 | -4.8% | 0.54% | -25.1% |
| Q1 2021 | $50,687,000 | -13.0% | 4,117,569 | -0.3% | 0.71% | +1.3% |
| Q4 2020 | $58,259,000 | +16.4% | 4,131,869 | -1.0% | 0.70% | -23.3% |
| Q3 2020 | $50,072,000 | -25.4% | 4,172,686 | +3.3% | 0.92% | -25.8% |
| Q2 2020 | $67,084,000 | +45.9% | 4,041,211 | 0.0% | 1.24% | -4.0% |
| Q1 2020 | $45,989,000 | +94.3% | 4,041,211 | +110.4% | 1.29% | +127.7% |
| Q4 2019 | $23,665,000 | – | 1,920,831 | – | 0.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,386,300 | $19,547,000 | 2.55% |
| EcoR1 Capital, LLC | 3,122,704 | $44,030,000 | 2.37% |
| Redmile Group, LLC | 4,131,869 | $58,259,000 | 0.70% |
| Boxer Capital, LLC | 1,501,058 | $21,165,000 | 0.68% |
| HighVista Strategies LLC | 69,727 | $983,000 | 0.63% |
| Baker Brothers Advisors | 3,821,740 | $53,887,000 | 0.20% |
| Highland Private Wealth Management | 93,998 | $1,326,000 | 0.12% |
| Sio Capital Management, LLC | 38,312 | $540,000 | 0.11% |
| Point72 Asset Management, L.P. | 1,195,725 | $16,860,000 | 0.08% |
| Granahan Investment Management | 246,299 | $3,473,000 | 0.08% |